Cargando…
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
BACKGROUND: Bisdioxopiperazine anti-cancer agents are inhibitors of eukaryotic DNA topoisomerase II, sequestering this protein as a non-covalent protein clamp on DNA. It has been suggested that such complexes on DNA represents a novel form of DNA damage to cells. In this report, we characterise the...
Autores principales: | Jensen, Lars H, Dejligbjerg, Marielle, Hansen, Lasse T, Grauslund, Morten, Jensen, Peter B, Sehested, Maxwell |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545072/ https://www.ncbi.nlm.nih.gov/pubmed/15575955 http://dx.doi.org/10.1186/1471-2210-4-31 |
Ejemplares similares
-
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021) -
A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193
por: Ling, Elise M., et al.
Publicado: (2022) -
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
por: Dejligbjerg, Marielle, et al.
Publicado: (2008) -
Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
por: Perkins, W. E., et al.
Publicado: (1982) -
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds
por: Hille, B van, et al.
Publicado: (1999)